Al18F-NOTA-LM3

N/A

Report date: 2025/11/20 11:38:26

NME

Base Information

Drug NameAl18F-NOTA-LM3

Drug Alias NameAl18F-NOTA-LM3

ClassificationRadiation-emitting products > Nuclides > Fluorine > 18FRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Radionuclide Drug Conjugates +[4]

Mechanisms of ActionSomatostatin receptor 2 antagonists

TargetsSomatostatin receptor 2

Therapy Area/IndicationsNeuroendocrine Tumors

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaPhase 2 Clinical

Originator CompaniesPeking Union Medical College Hospital

China Registration ClassN/A

Develop Information

Active CompaniesPeking Union Medical College Hospital

Inactive CompaniesN/A

Active IndicationsNeuroendocrine Tumors

Inactive IndicationsN/A

Other Information

ATC CodeN/A